Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.54 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390153 | 1.00 | ALOX15 (0.54) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL14879742 | 0.84 | ALOX15 (0.43) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL396749 | 0.82 | ALDH1A1 (0.61) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL22140388 | 0.79 | ALOX15 (0.39) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL15301192 | 0.79 | CASP1 (0.41) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL12732773 | 0.79 | ESRRA (0.49) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL30874683 | 0.78 | PTGDR2 (0.46) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL9248443 | 0.78 | PTGDR2 (0.46) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL6510666 | 0.78 | ALDH1A1 (0.67) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL19457567 | 0.78 | ALOX15 (0.38) | ALOX15ALDH1A1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-120035582-A | Pyridazinone compounds for the treatment of respiratory diseases | 病童医院 | 2025-05-23 | — | — | CN | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-112679635-B | Preparation method of supported metallocene catalyst and catalyst prepared by preparation method | 中国石油化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2023-11-28 | — | — | US | disclosed |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2023-11-28 | — | — | US | disclosed |
| CN-116157387-A | Isoquinoline compounds and their use in the treatment of AhR imbalance | 德玛万科学有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230124135-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2023-04-20 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| WO-1996033716-A1 | RARβ SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY | ALLERGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1996020938-A1 | ACETYLENES DISUBSTITUTED WITH 2-TETRAHYDROPYRANOXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020937-A1 | ACETYLENES DISUBSTITUTED WITH HYDROXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5534641-A | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-07-09 | — | — | US | disclosed |
| US-5498795-A | ANTITUMOR AGENTS, SKIN DISORDERS, ATHEROSCLEROSIS, PROSTATE CANCER AND AUTOIMMUNE DISEASES | ALLERGAN, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| CN-1117960-A | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124135-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | ALOX15 542/4885ALDH1A1 173/4885SMN1; SMN2 4218/4885 |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | ALOX15 542/4885ALDH1A1 173/4885SMN1; SMN2 4218/4885 |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | ALOX15 542/4885ALDH1A1 173/4885SMN1; SMN2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.